Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal Shah(Boston College), Armin Ghobadia(Washington University in St. Louis), Kristen M. O’Dwyer(University of Rochester Medical Center), Patrick J. Stiff(Loyola University Medical Center), Martha Arellano(Memorial Sloan Kettering Cancer Center), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Deepa Jeyakumar(Dana-Farber Cancer Institute), Lang Zhou(Kite (United States)), Roch Houot(Inserm), Gary J. Schiller(Fred Hutch Cancer Center), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Olalekan O. Oluwole(Vanderbilt University), Daqin Mao(Tufts Medical Center), Monique C. Minnema(University Medical Center Utrecht), Maria R. Baer(University of Maryland, Baltimore), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Nicolas Boissel(Inserm), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), William G. Wierda(University of Maryland, Baltimore), Michael R. Bishop(University of Chicago), Yi Lin, Max S. Topp(Universitätsklinikum Würzburg), Jae H. Park(Memorial Sloan Kettering Cancer Center), Sabina Adhikary(Kite (United States)), Marion Subklewe(LMU Klinikum), Rita Damico Khalid, Petra Schuberth(Kite (United States))
Cited by 33
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k